RSP 2240: Chapter 8 (Xanthines), Chapter 9 (Mucus-controlling drugs), Chapter 10 (Surfactants)

General mechanism and clinical effects of xanthines:

Alkaloid agents that promote smooth muscle relaxation, providing mild bronchodilation and mild central nervous system stimulation.

Two primary therapeutic drugs belonging to the methylxanthine group:

Theophylline and caffeine citrate.

Vascular actions of methylxanthines on systemic versus cerebral blood vessels:

Cause peripheral and coronary vasodilation while producing cerebral vasoconstriction.

Three key respiratory actions produced by theophylline:

Produces mild bronchodilation, provides mild anti-inflammatory effects, and increases diaphragmatic muscle contractility.

Role of theophylline in the clinical treatment of asthma and COPD:

Serves as an alternative or third-line maintenance therapy, reserved for when first-line relievers and controllers ($\beta_2$-agonists, anticholinergics like ipratropium, and corticosteroids) fail to provide control.

Therapeutic serum concentration range for theophylline:

$$10\text{ to }20\,\mu\text{g/mL}$$

Clinical toxicities seen with elevated theophylline serum levels:

Nausea occurs at $>20\,\mu\text{g/mL}$, cardiac arrhythmias occur at $>30\,\mu\text{g/mL}$, and seizures occur at $40\text{ to }45\,\mu\text{g/mL}$.

Standard initial theophylline loading dose:

$$5\,\text{mg/kg}$$

Primary organ sites responsible for theophylline metabolism and elimination:

Metabolized primarily by the liver and excreted by the kidneys.

First-line methylxanthine agent of choice for Apnea of Prematurity (AOP):

Caffeine citrate, preferred over theophylline due to a wider therapeutic margin and fewer side effects.

Two drug classes whose actions can be altered or antagonized by theophylline:

Benzodiazepines and nondepolarizing neuromuscular blocking agents.

General mechanism and clinical effects of xanthines:

Alkaloid agents that promote smooth muscle relaxation, providing mild bronchodilation and mild central nervous system stimulation.

Two primary therapeutic drugs belonging to the methylxanthine group:

Theophylline and caffeine citrate.

Vascular actions of methylxanthines on systemic versus cerebral blood vessels:

Cause peripheral and coronary vasodilation while producing cerebral vasoconstriction.

Three key respiratory actions produced by theophylline:

Produces mild bronchodilation, provides mild anti-inflammatory effects, and increases diaphragmatic muscle contractility.

Role of theophylline in the clinical treatment of asthma and COPD:

Serves as an alternative or third-line maintenance therapy, reserved for when first-line relievers and controllers ($\beta_2$-agonists, anticholinergics like ipratropium, and corticosteroids) fail to provide control.

Therapeutic serum concentration range for theophylline:

$$10\text{ to }20\,\mu\text{g/mL}$$

Clinical toxicities seen with elevated theophylline serum levels:

Nausea occurs at $>20\,\mu\text{g/mL}$, cardiac arrhythmias occur at $>30\,\mu\text{g/mL}$, and seizures occur at $40\text{ to }45\,\mu\text{g/mL}$.

Standard initial theophylline loading dose:

$$5\,\text{mg/kg}$$

Primary organ sites responsible for theophylline metabolism and elimination:

Metabolized primarily by the liver and excreted by the kidneys.

First-line methylxanthine agent of choice for Apnea of Prematurity (AOP):

Caffeine citrate, preferred over theophylline due to a wider therapeutic margin and fewer side effects.

Two drug classes whose actions can be altered or antagonized by theophylline:

Benzodiazepines and nondepolarizing neuromuscular blocking agents.

Two primary structures responsible for mucus production in the conducting airways:

Surface goblet cells (epithelial cells) and submucosal mucus glands (located below the epithelial surface, producing the majority of airway mucus).

Primary physiological functions of airway mucus:

Lubrication, waterproofing of the respiratory tract, protection against inflammation, and entrapment of inhaled microorganisms and foreign particles (it does not improve gas exchange).

Distinction between mucus and sputum:

Mucus refers to the normal secretions lining the respiratory tract, whereas sputum refers to expectorated secretions that contain mucus mixed with cellular debris, microorganisms, and oropharyngeal/nasopharyngeal secretions (saliva).

Common clinical and environmental factors that impair mucociliary clearance:

Cigarette smoke (primary airway irritant that paralyzes cilia), environmental pollutants, and mechanical ventilation lacking adequate active humidification or a heat and moisture exchanger (HME).

Clinical interpretations of common sputum colors:

• Clear: Normal secretions
• Mucoid (white/gray): Chronic bronchitis
• Brown/dark: Old blood
• Bright red: Active hemoptysis (e.g., airway trauma, tuberculosis)
• Pink frothy: Pulmonary edema
• Green/foul-smelling: Stagnant purulent secretions, frequently seen in bronchiectasis

Mechanism of action and rheological goals of mucolytic therapy:

Liquefies thick mucus to a watery state to improve mucociliary transportability and cough clearance by decreasing mucus viscosity and adhesivity while preserving elasticity.

Two pulmonary disease states primarily indicated for mucolytic administration:

Cystic fibrosis (CF) and bronchiectasis.

Generic and trade names of the two primary mucolytic agents:

N-acetylcysteine (Mucomyst) and dornase alfa (Pulmozyme).

Specific mechanism of action and primary indication for dornase alfa (Pulmozyme):

Selectively cleaves and digests extracellular DNA released by degenerating neutrophils in purulent secretions, indicated specifically to thin thick mucus in cystic fibrosis.

Standard dosing, administration, and storage requirements for dornase alfa:

Administered as $2.5\,\text{mg}$ in a $2.5\,\text{mL}$ clear, colorless unit-dose ampule via nebulizer once daily; must be refrigerated and protected from light.

Clinical concentration and purpose of hyperosmolar saline in respiratory therapy:

$7\%$ hypertonic saline, nebulized as an irritant to induce coughing for sputum specimen induction and to enhance mucociliary transport and lung clearance.

General pharmacological mechanism and clinical effects of xanthines

Alkaloid agents that promote smooth muscle relaxation, providing mild bronchodilation and mild central nervous system stimulation.

Two primary therapeutic drugs belonging to the methylxanthine class

Theophylline and caffeine citrate.

Vascular effects of methylxanthines on peripheral versus cerebral blood vessels

Cause peripheral and coronary vasodilation while producing cerebral vasoconstriction.

Three key respiratory actions produced by theophylline

Produces mild bronchodilation, provides mild anti-inflammatory effects, and increases diaphragmatic muscle contractility.

Clinical role of theophylline in the management of asthma and COPD

Serves as an alternative or third-line maintenance therapy when first-line relievers and controllers ($\beta_2$-agonists, anticholinergics like ipratropium, and corticosteroids) fail to achieve control.

Therapeutic serum concentration range for theophylline

$$10\text{ to }20\,\mu\text{g/mL}$$

Serum theophylline concentrations associated with specific toxicities (nausea, arrhythmias, seizures)

Nausea occurs at $>20\,\mu\text{g/mL}$, cardiac arrhythmias occur at $>30\,\mu\text{g/mL}$, and seizures occur at $40\text{ to }45\,\mu\text{g/mL}$.

Standard initial loading dose for theophylline

$$5\,\text{mg/kg}$$

Primary organ sites responsible for theophylline metabolism and elimination

Metabolized primarily by the liver and excreted by the kidneys.

First-line methylxanthine agent of choice for Apnea of Prematurity (AOP)

Caffeine citrate, preferred over theophylline due to a wider therapeutic margin and fewer side effects.

Two drug classes whose actions can be altered or antagonized by theophylline

Benzodiazepines and nondepolarizing neuromuscular blocking agents.

Two primary anatomical structures responsible for mucus production in conducting airways

Surface goblet cells (epithelial cells) and submucosal mucus glands (located beneath the epithelium, producing the majority of secretions).

Primary physiological functions of airway mucus

Provides lubrication, waterproofs the respiratory tract, protects against inflammation, and entraps inhaled microorganisms and foreign particles (it does not improve gas exchange).

Distinction between respiratory mucus and sputum

Mucus refers to normal secretions lining the respiratory tract, whereas sputum refers to expectorated secretions containing mucus mixed with cellular debris, microorganisms, and saliva.

Common clinical and environmental factors that impair mucociliary clearance

Cigarette smoke (primary irritant that paralyzes cilia), environmental pollutants, and mechanical ventilation lacking adequate humidification or a heat and moisture exchanger (HME).

Clinical interpretations of common sputum colors

Clear: normal secretions; Mucoid (white/gray): chronic bronchitis; Brown/dark: old blood; Bright red: active hemoptysis (e.g., trauma, tuberculosis); Pink frothy: pulmonary edema; Green/foul-smelling: stagnant purulent secretions, frequently seen in bronchiectasis.

Mechanism of action and rheological goals of mucolytic therapy

Liquefies thick mucus to a watery state to improve mucociliary transportability and cough clearance by decreasing viscosity and adhesivity while preserving elasticity.

Two pulmonary disease states primarily indicated for mucolytic administration

Cystic fibrosis (CF) and bronchiectasis.

Generic and trade names of the two primary mucolytic agents

N-acetylcysteine (Mucomyst) and dornase alfa (Pulmozyme).

Specific mechanism of action and primary indication for dornase alfa (Pulmozyme)

Selectively cleaves and digests extracellular DNA released by degenerating neutrophils in purulent secretions, indicated specifically to thin thick mucus in cystic fibrosis.

Standard dosing, administration, and storage requirements for dornase alfa

Administered as $2.5\,\text{mg}$ in a $2.5\,\text{mL}$ clear unit-dose ampule via nebulizer once daily; must be refrigerated and protected from light.

Clinical concentration and purpose of hyperosmolar saline in respiratory care

$7\%$ hypertonic saline, nebulized as an irritant to induce coughing for sputum specimen induction and to enhance mucociliary clearance.

Definition of surface tension in pulmonary physiology

The attractive force exerted by like liquid molecules at an air-liquid interface that pulls surface molecules inward, creating tension and causing liquid droplets or alveoli to resist expansion.

LaPlace's Law as applied to an alveolus with a single air-liquid interface

$\text{Pressure} = \frac{2 \times \text{Surface Tension}}{\text{Radius}}$, showing that as alveolar radius decreases, higher distending pressure is required to keep it open unless surface tension is reduced.

Primary physiological purposes of pulmonary surfactant

Lowers alveolar surface tension to keep alveoli open at end-expiration, maintains airway patency, prevents alveolar collapse (atelectasis), enhances bacterial killing, and regulates the inflammatory response by decreasing inflammatory mediator release.

Primary clinical indication for exogenous surfactant administration

Treatment or prevention of respiratory distress syndrome (RDS) in premature newborns caused by surfactant deficiency.

Distinction between prophylactic and rescue surfactant therapy

Prophylactic treatment is administered immediately after birth (within $15\,\text{minutes}$) to high-risk premature infants, whereas rescue treatment is administered once clinical signs of RDS develop.

Three USFDA-approved exogenous surfactant preparations (trade and generic names)

Curosurf (poractant alfa), Survanta (beractant), and Infasurf (calfactant).

Chemical composition of endogenous pulmonary surfactant

Composed of $85\text{ to }90\%$ lipids (predominantly dipalmitoylphosphatidylcholine/DPPC, responsible for reducing surface tension) and $10\%$ surfactant-associated proteins (SP-A, SP-B, SP-C, SP-D).

Cellular site of pulmonary surfactant synthesis, storage, and secretion

Synthesized in alveolar Type II pneumocytes, stored within intracellular lamellar bodies, and secreted into the alveolus via exocytosis.

Recycling efficiency and basal secretion rate of pulmonary surfactant

Approximately $90\text{ to }95\%$ is cleared from the alveoli, reprocessed, and resecreated by Type II cells, with secretion occurring at a rate of roughly $10\%$ of the intracellular pool per hour.

Source, starting material, and standard initial dose of Survanta (beractant)

Natural modified bovine (cow) lung extract, administered at $4\,\text{mL/kg}$ of birth weight by direct intratracheal instillation.

Source, preparation method, and standard dose of Infasurf (calfactant)

Natural calf lung extract obtained via bronchoalveolar lavage (BAL), administered at $3\,\text{mL/kg}$ of birth weight by intratracheal instillation every $12\,\text{hours}$ as needed.

Source and generic name of Curosurf

Natural porcine (pig) lung extract, generically known as poractant alfa.

Primary hazards and acute complications of exogenous surfactant administration

Transient airway obstruction and desaturation from liquid instillation, overventilation and hypocarbia from rapid compliance improvement, hyperoxygenation (elevated $\text{PaO}_2$), bradycardia or apnea during instillation, and pulmonary hemorrhage.

Proper storage and preparation technique for surfactant suspensions prior to administration

Stored in a refrigerator; if particles have settled, do not shake vigorously, but rather warm to room temperature and gently invert or swirl the vial slowly before drawing up.

Immediate physiological changes indicating successful surfactant administration

Rapid improvement in lung compliance and oxygenation, evidenced by pulse oximetry ($\text{SpO}<em>2$) rising within $2\text{ to }3\,\text{minutes}$, requiring immediate weaning of ventilator pressures and $\text{FiO}</em>2$.

Investigational and future therapeutic indications for exogenous surfactant beyond neonatal RDS

Meconium aspiration syndrome (MAS), severe neonatal pneumonia, viral bronchiolitis, and acute respiratory distress syndrome (ARDS) in pediatric and adult patients.